Integrated Parkinson’s Database

The database includes integrated and standardized data from both PD observational studies and randomized clinical trials and contains thousands of participants’ data, anonymized and deidentified.

Integrated Parkinson’s Database

The database includes integrated and standardized data from both PD observational studies and randomized clinical trials and contains thousands of participants’ data, anonymized and deidentified. The database covers over 600 variables, such as demographic information, clinical measures, medication usage data, dropouts, and more.

While the database is rich in patient-level outcome measures, it contains limited biomarker and genetics data and does not include any digital health technology data at this time, though we actively strive to acquire additional studies to enrich the database.

We would like to thank our collaborators for their generous contributions to the CPP integrated Parkinson’s Database. View acknowledgements.

Observational Trials Included in the CPP Database

Study NameContributorParticipantsReferenceNCT
Parkinson’s Progression Marker Initiative (PPMI) Biomarker StudyThe Michael J. Fox Foundation for Parkinson’s Research1563 early PDProg Neurobio. 2011 95:629-35NCT01141023
CamPaIGNUniversity of Cambridge, UK142 early PDJNNP 2013;84: 1258-1264NA
Tracking Parkinson’s / PRoBaNDUniversity of Glasgow, UK1998 early PDJ Park Dis 2015 5:947-59NA
OPDC Discovery CohortUniversity of Oxford, UK877early PDJ Park Dis 2015 5:269-79NA
PICNICSUniversity of Cambridge280J Neurol Neurosurg Psychiatry 2020 Jul;91(7):695-702NA

Randomized Clinical Trials Included in the CPP Database

Study NameContributorParticipantsReferenceNCT
ADAGIOTeva1176Lancet Neurol. 2011 May;10(5):415-23NCT00256204
CONFIDENT-PD (Cogane)Junaxo & The Michael J. Fox Foundation for Parkinson’s Research425 early PDNCT01060878NCT01060878
DATATOPNINDS800 early PDNeurol. 1990;40: 1529-34.NA
ELLDOPAUniversity of Rochester &NINDS361 early PDN Engl J Med 2004; 351:2498-508.NA
FS-1University of Rochester &NINDS200 early PDClin Neuropharmacol. 2008; 31(3):141-50NCT00063193
FS-TOOUniversity of Rochester &NINDS213 early PDJAMA Neurol. 2014;71(6): 710–716.NCT00076492
Japan Azilect – TVP 1012/CCT-001Takeda267Parkinsonism Related Disord. 2019 Mar; 60:146-152NCT02337725
Japan Azilect – TVP 1012/CCT-001 – ExtTakeda267Parkinsonism Related Disord. 2019 Mar; 60:146-152NCT02337725
Japan Azilect – TVP-1012 –Phase 2/3Takeda463PLoS One. . 2022 Jan 25;17(1) :e0262796.NCT02337738
Japan Azilect – TVP –Phase 3Takeda241NCT02337764NCT02337764
NET-PD LS1University of Rochester &NINDS1741JAMA Neurol. 2016 Mar: 73(3): 321-8NCT00449865
NILO-PDUniversity of Rochester & Northwestern University76JAMA Neurol. 2021 Apr; 78(4): 497NCT03205488
PRECEPTTeva806Neurology. 2007 Oct 9;69(15):1480-90NCT00040404
SP512UCB273 early PDPark & Related Disord. 2012 Jun; 18(5):488–93NCT00594165
SP513UCB561 early PDMov Dis 2007; 22(16):2398–404
SURE PD2The Michael J. Fox Foundation for Parkinson’s Research & University of Rochester75JAMA Neurol. 2014; 71(2):141-50NCT00833690
SURE PD3Massachusetts General Hospital, University of Rochester, NINDS298JAMA 2021; 326(10):926-939NCT02642393
STEADY PD3University of Rochester & NINDS336Ann Intern Med. 2020 May 5;172(9):591-598NCT0216884